{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:19:36Z","timestamp":1791580776437,"version":"4.3.4"},"reference-count":141,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD) affects up to a quarter of the adult population in many developed and developing countries. This spectrum of liver disease ranges from simple steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis. The incidence of NASH is projected to increase by up to 56% over the next 10 years. There is growing epidemiological evidence that NAFLD has become the fastest-growing cause of hepatocellular carcinoma (HCC) in industrialized countries. The annual incidence of HCC varies between patients with NASH cirrhosis and patients with noncirrhotic NAFLD. In this review, NAFLD\/NASH-associated HCC will be described, including its epidemiology, risk factors promoting hepatocarcinogenesis, and management of HCC in patients with obesity and associated metabolic comorbidities, including preventive strategies and therapeutic approaches to address this growing problem.<\/jats:p>","DOI":"10.3390\/cancers15225458","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T09:23:43Z","timestamp":1700213023000},"page":"5458","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6681-2170","authenticated-orcid":false,"given":"Benedetta Maria","family":"Motta","sequence":"first","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry, Scuola Medica Salernitana, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0550-8201","authenticated-orcid":false,"given":"Mario","family":"Masarone","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry, Scuola Medica Salernitana, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Torre","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry, Scuola Medica Salernitana, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1399-6498","authenticated-orcid":false,"given":"Marcello","family":"Persico","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry, Scuola Medica Salernitana, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: A population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","article-title":"Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: A systematic review and meta-analysis","volume":"4","author":"Li","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_6","unstructured":"Rinella, M.E., Lazarus, J.V., Ratziu, V., Francque, S.M., Sanyal, A.J., Kanwal, F., Romero, D., Abdelmalek, M.F., Anstee, Q.M., and Arab, J.P. (2023). A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol., 101133."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.31420","article-title":"From NAFLD to MAFLD: Implications of a Premature Change in Terminology","volume":"73","author":"Younossi","year":"2021","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030","volume":"69","author":"Estes","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study","volume":"63","author":"Piscaglia","year":"2016","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9547613","DOI":"10.1155\/2018\/9547613","article-title":"Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease","volume":"2018","author":"Masarone","year":"2018","journal-title":"Oxidtive Med. Cell. Longev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/tra.12700","article-title":"Actin-spectrin scaffold supports open fenestrae in liver sinusoidal endothelial cells","volume":"20","author":"Zapotoczny","year":"2019","journal-title":"Traffic"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00018-023-04966-7","article-title":"Liver endothelial cells in NAFLD and transition to NASH and HCC","volume":"80","author":"Velliou","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: Trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.14309\/ajg.0000000000000643","article-title":"Gender Matters: Characteristics of Hepatocellular Carcinoma in Women from a Large, Multicenter Study in the United States","volume":"115","author":"Phipps","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4254\/wjh.v11.i1.1","article-title":"Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review","volume":"11","author":"Desai","year":"2019","journal-title":"World J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/MCG.0000000000001172","article-title":"Among Medicare Patients with Hepatocellular Carcinoma, Non-alcoholic Fatty Liver Disease is the Most Common Etiology and Cause of Mortality","volume":"54","author":"Hester","year":"2020","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/ajg.2011.327","article-title":"Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma","volume":"107","author":"Kawamura","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/jgh.14448","article-title":"Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients","volume":"34","author":"Ito","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cld.2020.06.001","article-title":"The Changing Global Epidemiology of Hepatocellular Carcinoma","volume":"24","author":"Caines","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cgh.2012.10.001","article-title":"Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review","volume":"10","author":"White","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.21037\/hbsn.2019.08.08","article-title":"Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians","volume":"10","author":"Geh","year":"2021","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"51","author":"Ascha","year":"2010","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: Current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Alexander, M., Loomis, A.K., van der Lei, J., Duarte-Salles, T., Prieto-Alhambra, D., Ansell, D., Pasqua, A., Lapi, F., Rijnbeek, P., and Mosseveld, M. (2019). Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: Real-world study of 18 million patients in four European cohorts. BMC Med., 17.","DOI":"10.1186\/s12916-019-1321-x"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.24491","article-title":"The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study","volume":"54","author":"Bhala","year":"2011","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00535-008-2262-x","article-title":"Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"44","author":"Hashimoto","year":"2009","journal-title":"J. Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"E247","DOI":"10.1111\/j.1530-0277.2012.01900.x","article-title":"Hepatic and extrahepatic malignancies in cirrhosis caused by nonalcoholic steatohepatitis and alcoholic liver disease","volume":"37","author":"Kodama","year":"2013","journal-title":"Alcohol Clin. Exp. Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Marot, A., Henrion, J., Knebel, J.F., Moreno, C., and Deltenre, P. (2017). Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0186715"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients with Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study","volume":"155","author":"Castellanos","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1440-1746.2008.05640.x","article-title":"Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C","volume":"24","author":"Yatsuji","year":"2009","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/apt.14937","article-title":"Systematic review with meta-analysis: Risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases","volume":"48","author":"Stine","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of Hepatocellular Cancer in Patients with Non-Alcoholic Fatty Liver Disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.cgh.2021.05.002","article-title":"Incidence of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression","volume":"20","author":"Orci","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic Fatty Liver Disease 2020: The State of the Disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.31014","article-title":"Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1136\/gutjnl-2016-313622","article-title":"High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: A national, population-based cohort study in 1.2 million men","volume":"67","author":"Tynelius","year":"2018","journal-title":"Gut"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.ejca.2012.02.063","article-title":"Excess body weight and the risk of primary liver cancer: An updated meta-analysis of prospective studies","volume":"48","author":"Chen","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1166440","DOI":"10.3389\/fimmu.2023.1166440","article-title":"Obesity contributes to hepatocellular carcinoma development via immunosuppressive microenvironment remodeling","volume":"14","author":"Yang","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/ijc.27645","article-title":"Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort","volume":"132","author":"Schlesinger","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.14218\/JCTH.2015.00001","article-title":"Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-alcoholic Fatty Liver Diseases","volume":"3","author":"Raff","year":"2015","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/hep.30858","article-title":"Diabetes Is Associated with Increased Risk of Hepatocellular Carcinoma in Patients with Cirrhosis from Nonalcoholic Fatty Liver Disease","volume":"71","author":"Yang","year":"2020","journal-title":"Hepatology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/2047487319886404","article-title":"The metabolic syndrome\u2014What is it and how should it be managed?","volume":"26","author":"Nilsson","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/hep.23593","article-title":"Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: The Framingham Heart Study","volume":"51","author":"Speliotes","year":"2010","journal-title":"Hepatology"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Rajesh, Y., and Sarkar, D. (2021). Association of Adipose Tissue and Adipokines with Development of Obesity-Induced Liver Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22042163"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e12997","DOI":"10.1111\/eci.12997","article-title":"Adipokine dysregulation and adipose tissue inflammation in human obesity","volume":"48","author":"Unamuno","year":"2018","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/jebm.12270","article-title":"Cigarette smoking as a risk factor for the development of and mortality from hepatocellular carcinoma: An updated systematic review of 81 epidemiological studies","volume":"10","author":"Helbling","year":"2017","journal-title":"J. Evid. Based Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41416-018-0007-z","article-title":"Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project","volume":"118","author":"Petrick","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1756284819858470","DOI":"10.1177\/1756284819858470","article-title":"Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: Rationale and prospects for therapeutic intervention","volume":"12","author":"Mouzaki","year":"2019","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cgh.2018.08.065","article-title":"Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function","volume":"17","author":"Sharpton","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.transproceed.2016.01.077","article-title":"Profile of Gut Microbiota Associated with the Presence of Hepatocellular Cancer in Patients with Liver Cirrhosis","volume":"48","author":"Grat","year":"2016","journal-title":"Transpl. Proc."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"Miele","year":"2009","journal-title":"Hepatology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/hep.30036","article-title":"Hepatocellular Carcinoma Is Associated with Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease","volume":"69","author":"Ponziani","year":"2019","journal-title":"Hepatology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1053\/j.gastro.2017.01.055","article-title":"Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease","volume":"152","author":"Tailleux","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"G554","DOI":"10.1152\/ajpgi.00223.2019","article-title":"Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy","volume":"318","author":"Chiang","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jcmgh.2021.01.012","article-title":"Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH","volume":"11","author":"Cariello","year":"2021","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","article-title":"Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis","volume":"60","author":"Ferslew","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrgastro.2017.119","article-title":"Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis","volume":"15","author":"Jia","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1053\/j.gastro.2016.01.037","article-title":"Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease","volume":"150","author":"Anstee","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/hep.31113","article-title":"PNPLA3 Genotype and Risk of Liver and All-Cause Mortality","volume":"71","author":"Stender","year":"2020","journal-title":"Hepatology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/hep.27490","article-title":"Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease","volume":"61","author":"Dongiovanni","year":"2015","journal-title":"Hepatology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jhep.2016.07.045","article-title":"The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans","volume":"65","author":"Luukkonen","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1093\/hmg\/ddp357","article-title":"The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver","volume":"18","author":"Beer","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jhep.2015.02.049","article-title":"Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease","volume":"63","author":"Kitamoto","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"Bianco","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hep.31238","article-title":"Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population","volume":"72","author":"Richardson","year":"2020","journal-title":"Hepatology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","article-title":"Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study","volume":"140","author":"Williams","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1478-3231.2008.01718.x","article-title":"Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus","volume":"29","author":"Leite","year":"2009","journal-title":"Liver Int."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2008.06.012","article-title":"Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: A systematic review","volume":"49","author":"Sookoian","year":"2008","journal-title":"J. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: Clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"101092","DOI":"10.1016\/j.molmet.2020.101092","article-title":"Dysregulated lipid metabolism links NAFLD to cardiovascular disease","volume":"42","author":"Deprince","year":"2020","journal-title":"Mol. Metab."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1111\/jgh.15589","article-title":"Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease","volume":"36","author":"Tamaki","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/hep.32542","article-title":"NAFLD-related hepatocellular carcinoma: The growing challenge","volume":"77","author":"Shah","year":"2023","journal-title":"Hepatology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","article-title":"Liver cirrhosis","volume":"371","author":"Schuppan","year":"2008","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cld.2019.07.007","article-title":"Portal Hypertension","volume":"23","author":"Turco","year":"2019","journal-title":"Clin. Liver Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.cgh.2012.05.008","article-title":"Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease","volume":"10","author":"Mendes","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Mantovani, A., and Dalbeni, A. (2021). Treatments for NAFLD: State of Art. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052350"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2016). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 64, 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jhep.2021.07.025","article-title":"Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention","volume":"75","author":"Lange","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Abenavoli, L., Boccuto, L., Federico, A., Dallio, M., Loguercio, C., Di Renzo, L., and De Lorenzo, A. (2019). Diet and Non-Alcoholic Fatty Liver Disease: The Mediterranean Way. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16173011"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.3748\/wjg.v24.i19.2083","article-title":"Mediterranean diet and nonalcoholic fatty liver disease","volume":"24","author":"Anania","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/ajcn\/nqz042","article-title":"Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: A systematic review, meta-analysis, and meta-regression","volume":"110","author":"Sharpton","year":"2019","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.soard.2018.12.002","article-title":"Bariatric surgery improves nonalcoholic fatty liver disease: A contemporary systematic review and meta-analysis","volume":"15","author":"Fakhry","year":"2019","journal-title":"Surg. Obes. Relat. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","article-title":"Bariatric\u2013metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): A multicentre, open-label, randomised trial","volume":"401","author":"Verrastro","year":"2023","journal-title":"Lancet"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/apt.16335","article-title":"Systematic review with meta-analysis: Bariatric surgery reduces the incidence of hepatocellular carcinoma","volume":"53","author":"Ramai","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","article-title":"An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH","volume":"79","author":"Tacke","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Ayada, I., van Kleef, L.A., Zhang, H., Liu, K., Li, P., Abozaid, Y.J., Lavrijsen, M., Janssen, H.L.A., van der Laan, L.J.W., and Ghanbari, M. (2023). Dissecting the multifaceted impact of statin use on fatty liver disease: A multidimensional study. EBioMedicine, 87.","DOI":"10.1016\/j.ebiom.2022.104392"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e33981","DOI":"10.1097\/MD.0000000000033981","article-title":"Statins on nonalcoholic fatty liver disease: A systematic review and meta-analysis of 14 RCTs","volume":"102","author":"Zhou","year":"2023","journal-title":"Medicine"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/MEG.0000000000002517","article-title":"Statin can reduce the risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"35","author":"Zhang","year":"2023","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jhep.2011.03.016","article-title":"The role of thiazolidinediones in non-alcoholic steatohepatitis\u2014A systematic review and meta analysis","volume":"55","author":"Mahady","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_98","unstructured":"Associazione Italiana per lo Studio del Fegato (AISF), Societ\u00e0 Italiana di Diabetologia (SID), Societ\u00e0 Italiana dell\u2019Obesit\u00e0 (SIO), Members of the Guidelines Panel, Coordinator, AISF Members, SID Members, SIO Members, and Metodologists (2022). Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Dig. Liver Dis., 54, 170\u2013182."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"102849","DOI":"10.1016\/j.dsx.2023.102849","article-title":"Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis","volume":"17","author":"Bandyopadhyay","year":"2023","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.freeradbiomed.2021.10.017","article-title":"Role of vitamin E in the treatment of non-alcoholic steatohepatitis","volume":"177","author":"Sumida","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/MCO.0b013e328357f747","article-title":"Vitamin E and nonalcoholic fatty liver disease","volume":"15","author":"Pacana","year":"2012","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1001\/jama.297.8.842","article-title":"Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: Systematic review and meta-analysis","volume":"297","author":"Bjelakovic","year":"2007","journal-title":"JAMA"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"c5702","DOI":"10.1136\/bmj.c5702","article-title":"Effects of vitamin E on stroke subtypes: Meta-analysis of randomised controlled trials","volume":"341","author":"Schurks","year":"2010","journal-title":"BMJ"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.2011.1437","article-title":"Vitamin E and the risk of prostate cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)","volume":"306","author":"Klein","year":"2011","journal-title":"JAMA"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Hadi, H., Vettor, R., and Rossato, M. (2018). Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth?. Antioxidants, 7.","DOI":"10.3390\/antiox7010012"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Campagna, R., and Vignini, A. (2023). NAD(+) Homeostasis and NAD(+)-Consuming Enzymes: Implications for Vascular Health. Antioxidants, 12.","DOI":"10.3390\/antiox12020376"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nm.3882","article-title":"Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization","volume":"21","author":"Hong","year":"2015","journal-title":"Nat. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bbrc.2018.11.008","article-title":"Alleviation of fatty liver in a rat model by enhancing N(1)-methylnicotinamide bioavailability through aldehyde oxidase inhibition","volume":"507","author":"Takeuchi","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.gendis.2022.03.019","article-title":"Nicotinamide N-methyltransferase and liver diseases","volume":"10","author":"Liang","year":"2023","journal-title":"Genes Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1039\/D1CB00134E","article-title":"Macrocyclic peptides as allosteric inhibitors of nicotinamide N-methyltransferase (NNMT)","volume":"2","author":"Zhang","year":"2021","journal-title":"RSC Chem. Biol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"12938","DOI":"10.1021\/acs.jmedchem.1c01094","article-title":"Potent Inhibition of Nicotinamide N-Methyltransferase by Alkene-Linked Bisubstrate Mimics Bearing Electron Deficient Aromatics","volume":"64","author":"Gao","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Lawitz","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/14728214.2021.1947240","article-title":"Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity","volume":"26","author":"Jepsen","year":"2021","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: A systematic review and meta-analysis","volume":"65","author":"Karagiannis","year":"2022","journal-title":"Diabetologia"},{"key":"ref_120","unstructured":"(2023, May 19). Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH. Available online: https:\/\/www.globenewswire.com\/news-release\/2023\/05\/19\/2672820\/23024\/en\/Intercept-Announces-Outcome-of-FDA-Advisory-Committee-Meeting-for-Obeticholic-Acid-as-a-Treatment-for-Pre-Cirrhotic-Fibrosis-due-to-NASH.html."},{"key":"ref_121","unstructured":"Food and Drug Administration (2023, May 19). Gastrointestinal Drugs Advisory Committee Meeting, Available online: https:\/\/www.fda.gov\/media\/168215\/download."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study","volume":"76","author":"Rinella","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Lefebvre, E., Moyle, G., Reshef, R., Richman, L.P., Thompson, M., Hong, F., Chou, H.L., Hashiguchi, T., Plato, C., and Poulin, D. (2016). Antifibrotic Effects of the Dual CCR2\/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0158156"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Anstee, Q.M., Neuschwander-Tetri, B.A., Wai-Sun Wong, V., Abdelmalek, M.F., Rodriguez-Araujo, G., Landgren, H., Park, G.S., Bedossa, P., Alkhouri, N., and Tacke, F. (2023). Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study. Clin. Gastroenterol. Hepatol.","DOI":"10.1016\/j.cgh.2023.04.003"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.gastro.2020.05.046","article-title":"Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?","volume":"165","author":"Ratziu","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jhep.2018.12.014","article-title":"Association between physical activity and risk of hepatobiliary cancers: A multinational cohort study","volume":"70","author":"Baumeister","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Wang, H., and Xiao, H. (2021). Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22095016"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1634\/theoncologist.2008-0185","article-title":"Sorafenib for the treatment of unresectable hepatocellular carcinoma","volume":"14","author":"Kane","year":"2009","journal-title":"Oncologist"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/1078-0432.CCR-20-3407","article-title":"FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma","volume":"27","author":"Casak","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1111\/j.1572-0241.2007.01481.x","article-title":"Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis","volume":"102","author":"Sanyal","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3748\/wjg.v17.i10.1237","article-title":"Diagnosis and therapy of ascites in liver cirrhosis","volume":"17","author":"Biecker","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1136\/gutjnl-2019-320221","article-title":"Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension","volume":"69","author":"Tripathi","year":"2020","journal-title":"Gut"},{"key":"ref_136","unstructured":"European Association for the Study of the Liver (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol., 69, 182\u2013236."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3350\/cmh.2012.18.3.258","article-title":"Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period","volume":"18","author":"Song","year":"2012","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Salaheldin, M., Aly, H., Lau, L., Afify, S., and El-Kassas, M. (2023). Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: The Next Threat after Viral Hepatitis. Diagnostics, 13.","DOI":"10.3390\/diagnostics13162631"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Taru, M.-G., and Lupsor-Platon, M. (2023). Exploring Opportunities to Enhance the Screening and Surveillance of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease (NAFLD) through Risk Stratification Algorithms Incorporating Ultrasound Elastography. Cancers, 15.","DOI":"10.3390\/cancers15164097"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Pinto, E., Meneghel, P., Farinati, F., Russo, F.P., Pelizzaro, F., and Gambato, M. (2023). Efficacy of immunotherapy in hepatocellular carcinoma: Does liver disease etiology have a role?. Dig. Liver Dis.","DOI":"10.1016\/j.dld.2023.08.062"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/22\/5458\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:24:56Z","timestamp":1760131496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/22\/5458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,17]]},"references-count":141,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["cancers15225458"],"URL":"https:\/\/doi.org\/10.3390\/cancers15225458","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,17]]}}}